Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Liaoning
-
Shenyang, Liaoning, China, 110004
- Shengjing Hospital of China Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Females 18 years to 40 years of age Diagnosed as PCOS by the 2003 Rotterdam criteria
- Overweight/obesity (BMI≥24 kg/m2)
- No pregnant plan in recent 6 months
- Written consent for participation in the study
Exclusion Criteria:
- type 1 or type 2 diabetes mellitus
- Subjects have other endocrine diseases, such as adrenal hyperplasias or tumor, androgen-secreting tumors, Cushing's syndrome, thyroid diseases, and hyperprolactinemia
- Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Serious systemic disease or malignant tumor
- History of pancreatitis (chronic, acute or recurrent)
- Body weight change ≥10% at 3 months before treatment
- Used oral contraceptives or sex hormone drugs in the past 1 month
- Used oral glucocorticoids in the past 1 month
- Substance (alcohol or drug) abuse or dependence within 3 months
- Heavy smokers (smokers who smoke 20 or more cigarettes a day) or heavy drinkers (>10g/d)
- Subjects have a severe systemic disease, such as cardiovascular system, Renal impairment (eGFR<60ml/min/1.73m2)
- Increase of transaminases up to < 2.5 times of upper limit of normal value
- Have a history of thromboembolic disease or thrombotic tendency
- Subjects in pregnant or lactating or within 1 year after delivery
- Subjects have an allergic history to the drugs used in the study
- Subjects have participated in other clinical researches of medicine within 1 month prior to randomization
- Use of metformin, glucagon-like peptide -1 receptor agonists, or weight loss medications (prescription or OTC) within 30 days before screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Metformin (BMI<24)
Subjects: PCOS patients whoseBMI<24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
|
Use Metformin for 3 months to treat PCOS
|
|
Experimental: Metformin (BMI≥24)
Subjects: PCOS patients whoseBMI≥24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
|
Use Metformin for 3 months to treat PCOS
|
|
Experimental: Combination (BMI<24)
Subjects: PCOS patients whoseBMI<24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
|
Use Metformin for 3 months to treat PCOS
Use Exenatide for 3 months to treat PCOS
|
|
Experimental: Combination (BMI≥24)
Subjects: PCOS patients whoseBMI≥24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
|
Use Metformin for 3 months to treat PCOS
Use Exenatide for 3 months to treat PCOS
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in body weight
Time Frame: 12 weeks
|
Change in body weight
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in body mass index (BMI)
Time Frame: 12 weeks
|
Change in body mass index (BMI)
|
12 weeks
|
|
Change in waist circumference(WC)
Time Frame: 12 weeks
|
Change in waist circumference(WC)
|
12 weeks
|
|
Change in Ferriman-Gallwey score
Time Frame: 12 weeks
|
Change in Ferriman-Gallwey score,the range of Ferriman-Gallwey score is 0-9, higher scores mean a worse outcome.
|
12 weeks
|
|
Change in Acne severity score
Time Frame: 12 weeks
|
Change in Acne severity score,the range of acne severity score is 0-9, higher scores mean a worse outcome.
|
12 weeks
|
|
Changes in frequency of menstrual cycle
Time Frame: 12 weeks
|
Changes in frequency of menstrual cycle
|
12 weeks
|
|
Changes in Blood Glucose and Insulin During the oral glucose tolerance test (OGTT)
Time Frame: 12 weeks
|
glucose obtained at 0,30,60 and 120 minutes during the OGTT.
|
12 weeks
|
|
Changes in Luteinizing Hormone (LH)
Time Frame: 12 weeks
|
Changes in Luteinizing Hormone (LH)
|
12 weeks
|
|
Changes in follicle stimulating hormone (FSH)
Time Frame: 12 weeks
|
Changes in follicle stimulating hormone (FSH)
|
12 weeks
|
|
Changes in LH/FSH
Time Frame: 12 weeks
|
Changes in LH/FSH
|
12 weeks
|
|
Changes in prolactin (PRL)
Time Frame: 12 weeks
|
Changes in prolactin (PRL)
|
12 weeks
|
|
Changes in progesterone (Prog)
Time Frame: 12 weeks
|
Changes in progesterone (Prog)
|
12 weeks
|
|
Changes in total testosterone (TT)
Time Frame: 12 weeks
|
Changes in total testosterone (TT)
|
12 weeks
|
|
Changes in free testosterone (FT)
Time Frame: 12 weeks
|
Changes in free testosterone (FT)
|
12 weeks
|
|
Changes in free androgen index (FAI)
Time Frame: 12 weeks
|
Changes in free androgen index (FAI)
|
12 weeks
|
|
Changes in sex hormone binding globulin (SHBG)
Time Frame: 12 weeks
|
Changes in sex hormone binding globulin (SHBG)
|
12 weeks
|
|
Changes in dehydroepiandrosterone sulfate (DHEAS)
Time Frame: 12 weeks
|
Changes in dehydroepiandrosterone sulfate (DHEAS)
|
12 weeks
|
|
Changes in anti-müllerian hormone (AMH)
Time Frame: 12 weeks
|
Changes in anti-müllerian hormone (AMH)
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Endocrine System Diseases
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Body Weight
- Polycystic Ovary Syndrome
- Overweight
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Obesity Agents
- Incretins
- Metformin
- Exenatide
Other Study ID Numbers
Other Study ID Numbers
- 2020PS624K
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.